BIO-B — Bio-Rad Laboratories, Inc.

Bio-Rad Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: Approximately $651 million, flat year-over-year and down 1.9% on a currency-neutral basis.
• Clinical Diagnostics Revenue: $399 million, up 2.6% reported and 8.3% currency-neutral.
• Life Science Revenue: $252 million, down 4.1% reported and 5.1% currency-neutral, primarily due to challenges in the academic research market.
• Gross Margin: 53.1% reported; non-GAAP gross margin improved to 53.9%.
• Operating Income: Approximately $73 million; non-GAAP operating margin at 12.5%.
• Net Income: Non-GAAP net income of $70 million, or $2.62 diluted EPS, compared to $71 million or $2.61 diluted EPS in Q2 2025.
• Share Repurchases: Approximately 110,000 shares repurchased for $32 million.

2. Strategic Updates and Business Highlights:

• Digital PCR Growth: Instrument revenue increased over 20%, driven by successful integration of Stilla Technologies and broad-based demand.
• Operational Efficiency Initiatives: Announced restructuring to enhance agility and efficiency, with expected annualized cost savings of $30-$35 million by 2027.
• AI Utilization: AI tools have accelerated product development, significantly reducing timeframes for software projects.
• China Market Adaptation: Local manufacturing capabilities established to enhance competitiveness in tenders.

3. Forward Guidance and Outlook:

• Full-Year Revenue Growth Expectation: Currency-neutral revenue growth projected between -3% and +0.5%. Life Science segment expected to decline between -3% and -1%, while Clinical Diagnostics is projected to grow between -3% and +1%.
• Q3 Revenue Guidance: Expected to be flat compared to Q2, with a mid-single-digit revenue ramp anticipated from Q3 to Q4.
• Gross Margin Guidance: Expected to remain between 53% and 54% for the full year.

4. Challenges and Points of Concern:

• Life Science Segment Weakness: Continued softness in the academic research market and challenges in process chromatography, which is expected to impact revenue.
• China Market Decline: Revenue from China declined in the high teens, attributed to order timing and reduced demand for life science instruments.
• Geopolitical Risks: Ongoing volatility in the Middle East affecting logistics and costs, with no immediate resolution in sight.
• Operational Headwinds: Anticipated $4 million headwind from order timing in clinical diagnostics and continued pressures from elevated logistics costs.

5. Notable Q&A Insights:

• Digital PCR Growth Drivers: Broad-based demand and successful transition to Stilla's systems are key contributors to strong instrument sales.
• Sartorius Stake Monetization: Management is considering tax implications and potential structures for monetization, though no immediate plans are in place.
• CEO Succession Planning: The Board is actively reviewing succession plans, considering both internal and external candidates.
• Restructuring Impact: Expected to provide incremental operating margin expansion by 40-50 basis points, with a focus on operational efficiency and innovation investments.
• Market Dynamics in China: The company is monitoring potential changes in reimbursement policies and overall healthcare dynamics in China.

Overall, Bio-Rad's Q2 2026 results reflect a mixed performance with notable strengths in digital PCR and clinical diagnostics, while facing challenges in the Life Science segment and geopolitical risks. The company is taking strategic steps to enhance operational efficiency and adapt to market conditions, with cautious optimism for the second half of the year.